Equiservices and clinical trials
0641.815.841 · rovalta.com · 26/09/2026
Equiservices and clinical trials
Financial year 2024 · Closed on 31/12/2024
Overview
Identity
Source · BCE/KBOEquiservices and clinical trials is a Private limited company incorporated in 2015. Its registered office is in Meise.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0641.815.841
- Incorporation
- 22/10/2015
- Legal form
- Private limited company
- Registered office
- Willem de Zwijgerlaan 12
1860 Meise · FlandreSee on map - Contributed capital
- 6 200,00 €
- Latest accounts
- 31/12/2024
Financials
Source · NBB, 9 filingsTrend over 9 financial years
| 2024 | 2023 | 2022 | 2021 | 2020 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 24,1 k € | -32.7% | 35,8 k € | +405% | 7,1 k € | -19.6% | 8,8 k € | -59.1% | 21,5 k € |
| EBITDA | 21,2 k € | -36.2% | 33,3 k € | +840% | 3,5 k € | -56.7% | 8,2 k € | -59.3% | 20,1 k € |
| Operating result | 16,7 k € | -41.9% | 28,8 k € | +995% | 2,6 k € | -63.5% | 7,2 k € | -54.0% | 15,6 k € |
| Net result | 11,9 k € | -41.7% | 20,4 k € | +1174% | 1,6 k € | -59.3% | 3,9 k € | -65.3% | 11,4 k € |
| Balance sheet | |||||||||
| Equity | 17,1 k € | +228% | 5,2 k € | +134% | -15,2 k € | +9.5% | -16,8 k € | +19.0% | -20,8 k € |
| Total assets | 129,9 k € | -2.1% | 132,7 k € | +4.4% | 127,1 k € | +280% | 33,4 k € | +34.4% | 24,8 k € |
| Cash | 51,5 k € | -18.1% | 62,9 k € | -12.9% | 72,2 k € | +616% | 10,1 k € | +7.8% | 9,4 k € |
| Debts | 112,7 k € | -11.5% | 127,4 k € | -10.4% | 142,3 k € | +183% | 50,2 k € | +10.1% | 45,6 k € |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20242 active · 4 ended
Active mandates
Ended mandates
Other companies at this address
Willem de Zwijgerlaan 12 1860 Meise| Company | CBE no. |
|---|---|
CAREY● Active | 0737.630.956 |
Financials
Full financial information
Source · NBB| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2019 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 31/08/2025 | 30/07/2024 | 25/08/2023 | 14/06/2022 | 25/08/2021 | 17/10/2020 |
| General meeting | 30/06/2025 | 30/06/2024 | 30/06/2023 | 27/05/2022 | 30/06/2021 | 08/09/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 9 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 31/12/2024 | 30/06/2025 | 31/08/2025 | Dutch | |
| Micro model | 31/12/2023 | 30/06/2024 | 30/07/2024 | Dutch | |
| Micro model | 31/12/2022 | 30/06/2023 | 25/08/2023 | Dutch | |
| Micro model | 31/12/2021 | 27/05/2022 | 14/06/2022 | Dutch | |
| Micro model | 31/12/2020 | 30/06/2021 | 25/08/2021 | Dutch | |
| Micro model | 31/12/2019 | 08/09/2020 | 17/10/2020 | Dutch | |
| Micro model | 31/12/2018 | 31/05/2019 | 13/08/2019 | Dutch | |
| Abridged model | 31/12/2017 | 30/06/2018 | 29/08/2018 | Dutch | |
| Abridged model | 31/12/2016 | 30/06/2017 | 31/08/2017 | Dutch |
Valuation
Indicative valuation
As an indication, this company is worth
between 100 k€ and 250 k€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20242 active · 4 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official GazetteSimilar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 202411,9 k €↓
- 2024Name changeEquiservices and clinical trials
- 2023Annual accounts 202320,4 k €↑
- 2022Annual accounts 20221,6 k €↓
- 2021Annual accounts 20213,9 k €↓
- 2021Name changeEQUISERVICES AND CLINICAL TRAILS
- 2020Annual accounts 202011,4 k €↑
- 2019Annual accounts 2019-8,9 k €↓
- 2018Annual accounts 2018241 €↑
- 2017Annual accounts 2017-21,8 k €↓
- 2016Annual accounts 2016-7,9 k €
- 22/10/2015IncorporationPrivate limited company